CGG201

CGG201 is an investigational gene therapy candidate developed by Suzhou Cure Genetics for the treatment of neurodegenerative diseases. The program utilizes the company's proprietary VELP (Virus-like rEcombinant Lipid Protein) platform, which is a non-viral delivery system designed to efficiently transport genetic payloads into the central nervous system. The VELP technology is engineered to combine the high delivery efficiency characteristic of viral vectors with the safety profile and low immunogenicity of non-viral systems, potentially overcoming common hurdles such as pre-existing immunity and limited cargo capacity. Currently in the preclinical stage, CGG201 aims to address the underlying genetic or molecular drivers of neural degeneration, although its specific biological target has not been publicly disclosed.